DDInter1508 DDInter1628
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Prasugrel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Prasugrel {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Prasugrel {u} (Compound) binds {v} (Gene) P2RY12
P2RY12 {u} (Gene) regulates {v} (Gene) COTL1
COTL1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Prasugrel {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) covaries with {v} (Gene) ACADS
ACADS {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Prasugrel {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) interacts with {v} (Gene) RLF
RLF {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Prasugrel {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Prasugrel {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) interacts with {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Cimetidine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Cimetidine {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Prasugrel {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) interacts with {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Prasugrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Prasugrel (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Prasugrel (Compound) binds P2RY12 (Gene) and P2RY12 (Gene) regulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Ruxolitinib (Compound)
Prasugrel (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) covaries with ACADS (Gene) and ACADS (Gene) is downregulated by Ruxolitinib (Compound)
Prasugrel (Compound) binds ALB (Gene) and ALB (Gene) interacts with RLF (Gene) and RLF (Gene) is upregulated by Ruxolitinib (Compound)
Prasugrel (Compound) binds ALB (Gene) and ALB (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Prasugrel (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) interacts with MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Ruxolitinib (Compound)
Prasugrel (Compound) binds ALB (Gene) and ALB (Gene) interacts with CDC45 (Gene) and CDC45 (Gene) is downregulated by Ruxolitinib (Compound)